(230f) Bilayer Tablet Compaction: Translation From a Single Stage Compaction Simulator to a Rotary Press
AIChE Annual Meeting
2013
2013 AIChE Annual Meeting
Pharmaceutical Discovery, Development and Manufacturing Forum
Advances in Predictive Scale Down Capabilities
Tuesday, November 5, 2013 - 10:35am to 11:00am
Fixed dose combination products (FDC) are formulations containing two or more active pharmaceutical
ingredients (API) combined within a unit dose. In recent years, FDCs have become increasingly popular in
several therapeutic areas because they offer convenience, a reduced pill burden, and cost savings for patients.
In cases when the APIs are chemically incompatible or multiple release profiles are desired, the dose must
be formulated as a layered tablet. However, layered tablets pose unique development and manufacturing
risks because of the fine balance required between maintaining sufficient physical separation between the layers
to mitigate chemical incompatibilities and ensuring that the tablet remains intact (i.e. avoid layer delamination)
throughout the manufacturing process and product shelf life. Challenges during the manufacture of layered
tablets can be difficult to resolve due to the limited mechanistic understanding of the compaction process. Thus,
the development process for layered tablet formulations has been largely trial-and-error, requiring significant
resource investments, especially when considering that layered tablet production on a rotary press requires
kilogram-quantities of materials.
In this work, the authors have sought to gain mechanistic understanding of the compaction process for layered
tablets to minimize resources required during product development, more specifically to better understand how
experimental factors (i.e. material selection, compaction conditions) impact layer interface strength. Since the
failure of layered tablets typically occurs due to delamination at the interface, a fundamental appreciation of
the governing mechanisms that impact interface strength is crucial in order to improve the overall mechanical
integrity of that layered tablet. A single station compaction simulator, fitted with a three-sensor instrumented die,
was used as a material-sparing tool (requires only grams of material) for the development of bilayer tablets and
to increase fundamental understanding of the compaction process. The instrumented die was used to measure the
die-wall pressure exerted by each layer of the bilayer tablet during the compaction process.
Bilayer combinations of placebo and active granulations over a range of compaction forces were examined in
this study. Young’s moduli and Poisson’s ratios, as well as additional elastic material properties described by
the Drucker-Prager-Cap model, were determined using measured die-wall pressure profiles for each material in
the study. Analysis of the die-wall pressure profiles during bilayer compaction yielded a correlation between
the residual stress within each of the layers after compaction and the interface strength of the bilayer tablet. The
level of residual stress experienced by different materials, when compressed as either the first or second layer in a
bilayer tablet, was related back to elastic material properties. Using this knowledge, select material combinations
were compressed as bilayer tablets on a rotary tablet press. The trends in tablet interface strength for tablets
produced on the compaction simulator were similar for those manufactured on the rotary press. However, it was
noted that for certain material combinations, tablets made on the compaction simulator and the rotary press did
not possess the same solid fraction when compacted under the same forces. When tablet strength was examined
as a function of solid fraction instead of compaction force, the compaction simulator was found to adequately
emulate the rotary press. Discrepancies between press compaction force and corresponding solid fractions were
related back to elastic material properties. In conclusion, the compaction simulator was found to be a useful
tool to develop bilayer tablet formulations at small scales, providing results that may be translated to larger scale
production on a rotary press.